
Healthcare systems across Europe are in transition. The established model of episodic, hospital-centred care is giving way to preventive and continuous care, driven by ageing populations, rising chronic disease prevalence, and the economic unsustainability of reactive treatment.
This transition requires new enabling infrastructure. Implantable medical devices that can sense, communicate, and respond independently inside the body are central to the shift toward continuous therapeutic management. For the first time, genuine closed-loop therapy becomes possible when independent implanted nodes can communicate wirelessly with each other, sensing in one location and treating in another.
FAT-IBC, Probingon's validated wireless intrabody communication subsystem, provides this enabling communication layer. It is the physical infrastructure on which the next generation of implantable therapeutic devices will be built, whether in neuromodulation or any field of bioelectric medicine where distributed sensing and stimulation are required.
As clinical wearables and implantable devices become increasingly integrated into coordinated body area networks, the communication layer that connects them becomes a foundational element of the healthcare architecture. Probingon's position is to license that layer to the OEM manufacturers who build the devices, rather than developing finished products directly.
For a detailed explanation of our business model, see our Investors page. For an overview of our technology platform, visit our FAT-IBC Body Area Networks page